BYDUREON PEN
LOE ApproachingNDASUBCUTANEOUSFOR SUSPENSION, EXTENDED RELEASE
Approved
Jan 2012
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
3/8 — Basic
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BYDUREON PEN is an extended-release subcutaneous suspension approved by AstraZeneca in 2012 for chronic disease management. The product utilizes a pen-based delivery system for patient convenience and compliance. Specific mechanism of action and indications are not disclosed in available data.
$61,000Part D
LOE Approaching2.3 years to LOEProduct is in late-stage lifecycle with only $61K in 2023 Part D spending and minimal claims volume, signaling a small commercial team focused on transition planning rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~3 years — strategic planning for patent cliff underway
Worked on BYDUREON PEN at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.